Prognostic evaluation of segmental ureterectomy combined with chemotherapy in high-grade non-metastatic ureteral cancer: a study based on the SEER database.
Nomogram
Prognostic anaylsis
Segmental ureterectomy
Ureteral cancer
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2024
23 10 2024
Historique:
received:
08
09
2024
accepted:
21
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
This study evaluates the survival outcomes of segmental ureterectomy (SU) combined with chemotherapy in patients with high-grade non-metastatic ureteral cancer (UC) using data from the SEER database. A total of 1757 patients with Grade III-IV non-metastatic UC were analyzed. Overall survival (OS) was assessed through Kaplan-Meier analysis, and independent prognostic factors were identified via Cox regression. A Nomogram model was developed and evaluated using the concordance index, area under the time-dependent ROC curve, calibration curves, and decision curve analysis. The 1-, 3-, and 5-year OS rates were 82.8%, 55.6%, and 42.8%, respectively. Age, treatment protocol, T stage, and N stage were significant prognostic factors. Both SU + chemotherapy and radical nephroureterectomy (RNU) + chemotherapy demonstrated comparable survival outcomes, outperforming surgery alone, particularly in patients aged 70 and older. The Nomogram demonstrated high predictive accuracy and clinical utility. These findings suggest that SU + chemotherapy offers survival benefits similar to RNU + chemotherapy, making it a viable option, especially for elderly patients or those with impaired renal function.
Identifiants
pubmed: 39443538
doi: 10.1038/s41598-024-77117-y
pii: 10.1038/s41598-024-77117-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25090Subventions
Organisme : Shanghai Huangpu District Medical Key Specialty Discipline Construction Project Fund
ID : 2023ZDZK01
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48. https://doi.org/10.3322/caac.21763 (2023).
doi: 10.3322/caac.21763
pubmed: 36633525
Roupret, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur. Urol. 84, 49–64. https://doi.org/10.1016/j.eururo.2023.03.013 (2023).
doi: 10.1016/j.eururo.2023.03.013
pubmed: 36967359
Seisen, T. et al. Oncologic outcomes of kidney-sparing surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the EAU non-muscle invasive bladder Cancer guidelines Panel. Eur. Urol. 70, 1052–1068. https://doi.org/10.1016/j.eururo.2016.07.014 (2016).
doi: 10.1016/j.eururo.2016.07.014
pubmed: 27477528
Seisen, T. et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 114, 733–740. https://doi.org/10.1111/bju.12631 (2014).
doi: 10.1111/bju.12631
pubmed: 24447471
Margulis, V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma collaboration. Cancer. 115, 1224–1233. https://doi.org/10.1002/cncr.24135 (2009).
doi: 10.1002/cncr.24135
pubmed: 19156917
Masson-Lecomte, A. et al. EAU Guidelines (EAU Guidelines Office, 2024).
Paciotti, M. et al. Is Segmental Ureterectomy Associated with Inferior Survival for Localized Upper-Tract Urothelial Carcinoma of the ureter compared to Radical Nephroureterectomy? Cancers (Basel). 15 https://doi.org/10.3390/cancers15051373 (2023).
Birtle, A. et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 395, 1268–1277. https://doi.org/10.1016/S0140-6736(20)30415-3 (2020).
doi: 10.1016/S0140-6736(20)30415-3
pubmed: 32145825
pmcid: 7181180
Xiong, G. et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J. Formos. Med. Assoc. 113, 521–526. https://doi.org/10.1016/j.jfma.2013.04.001 (2014).
doi: 10.1016/j.jfma.2013.04.001
pubmed: 23684217
Kaag, M. G. et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur. Urol. 58, 581–587. https://doi.org/10.1016/j.eururo.2010.06.029 (2010).
doi: 10.1016/j.eururo.2010.06.029
pubmed: 20619530
pmcid: 3677959
Zareba, P., Rosenzweig, B., Winer, A. G. & Coleman, J. A. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer. 123, 1741–1750. https://doi.org/10.1002/cncr.30516 (2017).
doi: 10.1002/cncr.30516
pubmed: 28152158
Xylinas, E. et al. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: a population-based study. Urol. Oncol. 35, 33 e21–33 e26. https://doi.org/10.1016/j.urolonc.2016.07.022 (2017).
Fajkovic, H. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J. Urol. 187, 845–851. https://doi.org/10.1016/j.juro.2011.10.158 (2012).
doi: 10.1016/j.juro.2011.10.158
pubmed: 22248522
Matin, S. F., Sfakianos, J. P., Espiritu, P. N., Coleman, J. A. & Spiess, P. E. Patterns of lymphatic metastases in Upper Tract Urothelial Carcinoma and proposed dissection templates. J. Urol. 194, 1567–1574. https://doi.org/10.1016/j.juro.2015.06.077 (2015).
doi: 10.1016/j.juro.2015.06.077
pubmed: 26094807
pmcid: 4896731
Roupret, M. et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2017 update. Eur. Urol. 73, 111–122. https://doi.org/10.1016/j.eururo.2017.07.036 (2018).
doi: 10.1016/j.eururo.2017.07.036
pubmed: 28867446
Dominguez-Escrig, J. L. et al. Potential benefit of Lymph Node Dissection during Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder Cancer. Eur. Urol. Focus. 5, 224–241. https://doi.org/10.1016/j.euf.2017.09.015 (2019).
doi: 10.1016/j.euf.2017.09.015
pubmed: 29158169
Qiu, Y. et al. Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study. Int. Urol. Nephrol. 55, 579–588. https://doi.org/10.1007/s11255-022-03429-5 (2023).
doi: 10.1007/s11255-022-03429-5
pubmed: 36472798
Slusarczyk, A. et al. Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study. Urol. Oncol. 42 (22 e21-22 e11). https://doi.org/10.1016/j.urolonc.2023.09.019 (2024).
Claps, F. et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J. Urol. 39, 4363–4371. https://doi.org/10.1007/s00345-021-03776-5 (2021).
doi: 10.1007/s00345-021-03776-5
pubmed: 34196758
Claps, F. et al. The Prognostic significance of histological subtypes in patients with muscle-invasive bladder Cancer: an overview of the current literature. J. Clin. Med. 13, 4349. https://doi.org/10.3390/jcm13154349 (2024).
doi: 10.3390/jcm13154349
pubmed: 39124615
pmcid: 11313590
Moschini, M. et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat. Rev. Urol. 14, 651–668. https://doi.org/10.1038/nrurol.2017.125 (2017).
doi: 10.1038/nrurol.2017.125
pubmed: 28895563
Douglawi, A. et al. Impact of variant histology on oncological outcomes in Upper Tract Urothelial Carcinoma: results from the ROBUUST Collaborative Group. Clin. Genitourin. Cancer. 21, 563–568. https://doi.org/10.1016/j.clgc.2023.05.011 (2023).
doi: 10.1016/j.clgc.2023.05.011
pubmed: 37301663